Drug General Information
Drug ID
D01DAW
Former ID
DCL000724
Drug Name
Bifeprunox
Synonyms
Bifeprunoxum; Bifeprunox [INN]; DU 127090; DU127090; Bifeprunoxum [INN-Latin]; Bifeprunox (USAN/INN); 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Discontinued in Phase 3 [536463]
Company
Solvay
Structure
Download
2D MOL

3D MOL

Formula
C24H23N3O2
Canonical SMILES
C1CN(CCN1CC2=CC=CC(=C2)C3=CC=CC=C3)C4=CC=CC5=C4OC(=O)N5
InChI
1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
InChIKey
CYGODHVAJQTCBG-UHFFFAOYSA-N
CAS Number
CAS 350992-13-1
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) 5-hydroxytryptamine 1A receptor Target Info Modulator
D(2) dopamine receptor Target Info Modulator
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapsehsa04015:Rap1 signaling pathway
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Serotonin receptors
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
Genes and (Common) Pathways Underlying Drug Addiction
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.